Brain natriuretic peptide: Disease marker or more in cardiovascular medicine?

Drugs of Today

Volumn 37, Issue 7, 2001, Pages 463-476

  Doggrel, Sheila A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0042885425     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Sudoh, T., Kangawa, K., Minamino, N., Matsuo, H. A new natriuretic peptide in porcine brain. Nature 1988, 332: 78-81.
2. Kambayashi, Y., Nakao, K., Muroyama, M. et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett 1990, 259: 341-5.
3. Tamura, N., Ogawa, Y., Chusho, H. et al. Cardiac fibrosis in mice lacking natriuretic peptide. Proc Nat Acad Sci USA 2000, 11: 4239-44.
4. Kohno, M., Horio, T., Yodokawa, K. et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992, 92: 29-34.
5. Buckley, M.G., Markandu, N.D., Miller, M.A., Sagnella, G.A., MacGregor, G.A. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Hum Hypertens 1993, 7: 245-50.
6. Kohno, M., Horio, T., Yokokawa, K. et al. Atrial and brain natriuretic peptides: Secretion during exercise in patients with essential hypertension and modulation by acute angiotensin-converting enzyme inhibition. Clin Exp Pharmacol Physiol 1992, 19: 193-200.
7. Kohno, M., Horio, T., Yokokawa, K., Akioka, K., Ikeda, M., Takeda, T. Pulmonary arterial brain natriuretic peptide concentration and cardiopulmonary hemodynamics during exercise in pa-tients with essential hypertension. Metabolism 1992, 41: 1273-5.
8. Nishikimi, T., Yoshihara, F., Morimoto, A. et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996, 28: 22-30.
9. Kohno, M., Horio, T., Yokokawa, K. et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: Changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995, 98: 257-65.
10. Suzuki, M., Yamamoto, K., Watanabe, S., Iwata, T., Hamada, M., Hiwada, K. Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. Am J Med 2000, 108: 627-33.
11. Yu, C.M., Sanderson, J.E. Plasma brain natriuretic peptide - An independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1999, 1: 59-65.
12. Mukoyama, M., Nakao, K., Hosoda, K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991, 87: 1402-12.
13. Hasegawa, K., Fujiwara, H., Doyama, K. et al. Ventricular expression of brain natriuretic peptides in dilated cardiomyopathy. An immunohistocytochemical study of the endomyocardial biopsy specimens using specific monoclonal antibodies. Am J Pathol 1993, 142: 107-16.
14. Yasue, H., Yoshimura, M., Sumida, H. et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994, 90: 195-203.
15. Yoshimura, M., Yasue, H., Okumura, K. et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993, 87: 464-9.
16. Matsumoto, A., Hirata, Y., Monomura, S. et al. Effects of exercise on plasma levels of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. Am Heart J 1995, 129: 139-45.
17. Nishigaki, K., Tomita, M., Kagawa, K. et al. Marked expression of plasma brain natriuretic pep-tide is a special feature of hypertrophie obstructive cardiomyopathy. J Am Coll Cardiol 1996, 28: 1234-42.
18. Takemura, G., Takatsu, T., Doyama, K. et al. Expression of atrial and brain natriuretic peptides and their genes in heart of patients with cardiac amyloidosis. J Am Coll Cardiol 1998, 15: 754-65.
19. Tsutamoto, T., Wada, A., Maeda, K. et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997, 96: 509-16.
20. Yamada, Y., Goto, J., Yokota, M. Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. Cardiology 1997, 88: 401-7
21. Adachi, K., Kawai, H., Saito, M. et al. Plasma levels of brain natriuretic peptide as an index for evaluation of cardiac function in female gene carriers of Duchenne muscular dystrophy. Intern Med 1997, 36: 497-500.
22. Suzuki, T., Hayashi, D., Yamazaki, T. et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998, 136: 362-3.
23. Nousiainen, T., Jantunen, E., Vanninen, E., Remes, J., Vuolteenaho, O., Hartikainen, J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999, 62: 135-41.
24. Kikuta, K., Yasue, H., Yoshimura, M. et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996, 132: 101-7.
25. Marumoto, K., Hamada, M., Hiwada, K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Colch) 1995, 88: 551-6.
26. Mair, R., Mair, J., Bleier, J., Hormann, C., Balogh, D., Puschendorf, B. Augmented release of brain natriuretic peptide during reperfusion of the human heart after cardioplegic cardiac arrest. Clin Chim Acta 1997, 261: 57-68.
27. Mukoyama, M., Nakao, K., Obata, K., et al. Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun 1991, 180: 431-6.
28. Morita, E., Yasue, H., Yoshimura, M. et al. Increased plasma levels of brain natriuretic peptide In patients with acute myocardial infarction. Circulation 1993, 88: 82-91.
29. Arakawa, N., Nakamura, M., Aoki, H., Hiramori, K. Relationship between plasma levels of brain natriuretic peptide and myocardial infarct size. Cardiology 1994, 85: 334-40.
30. Foy, S.M., Crozier, I.G., Richards, A.M. et al. Neurohormonal changes after acute myocardial infarction. Relationship with haemodynamic indices and effects of ACE inhibition. Eur Heart J 1995, 16: 770-8.
31. Arakawa, N., Nakamura, M., Aoki, H., Hiramori, K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996, 27: 1656-61.
32. Omland, T., Aakvaag, A., Bonarjee, V.V. et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996, 93: 1963-9.
33. Richards, A.M., Nicholls, M.G., Yandle, T.G. et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart 1999, 81: 114-20.
34. Sumida, H., Yasue, H., Yoshimura, M. et al. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 1995, 25: 1105-10.
35. Morimoto, A., Nishikimi, T., Takaki, H. et al. Effect of exercise on plasma adrenomedullin and natriuretic peptide levels in myocardial infarction. Clin Exp Pharmacol Physiol 1997, 24: 15-20.
36. Friedl, W., Mair, J., Thomas, S., Pichler, M., Puschendorf, B. Natriuretic peptides and cyclic 3′,5′-monophosphate in asymptomatic and symptomatic left ventricular dysfunction. Heart 1996, 76: 129-36.
37. Omland, T., Aakvaag, A., Vik-Mo, H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996, 76: 232-7.
38. McDonagh, T.A., Robb, S.D., Murdoch, D.R. et al. Biomedical detection of left-ventricular systolic dysfunction. Lancet 1998, 351: 9-13.
39. McClure, S.J., Caruana, L., Davie, A.P., Goldthorp, S., McMurray, J.J. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998, 317: 516-9.
40. Smith, H., Pickering, R.M., Struthers, A., Simpson, I., Mant, D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: Observational study. BMJ 2000, 320: 906-8.
41. Luchner, A., Burnett, J.C., Jougasaki, M. et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000, 18: 1121-8.
42. Tanaka, T., Hasegawa, K., Fujita, M. et al. Marked elevation of brain natriuretic peptide levels in pericardial fluid is closely associated with left ventricular dysfunction. J Am Coll Cardiol 1998, 31: 399-403.
43. Hunt, P.J., Richards, A.M., Nicholls, A.M., Yandle, T.G., Doughty, R.N., Espiner, E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocr 1997, 47: 287-96.
44. Richards, A.M., Nicholls, M.G., Yandle, T.G. et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998, 19: 1921-9.
45. Murdoch, D.R., McDonagh, T.A., Byrne, J. et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999, 138: 1126-32.
46. Troughton, R.W., Frampton, C.M., Yandle, T.G., Espiner, E.A., Nicholls, M.G., Richards, A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355: 1126-30.
47. Nagaya, N., Nishikini, T., Okano, Y. et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998, 31: 202-8.
48. Nagaya, N., Nishikimi, T., Uematsu, M. et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102: 865-70.
49. Matsuo, K., Nishikimi, T., Yutani, C. et al. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. Circulation 1998, 98: 2433-40.
50. Itoh, H., Sugawa, N., Nanno, H. et al. Impaired guanosine 3′,5′-cyclic phosphate production in severe pregnancy-induced hypertension with high plasma levels of atrial and brain natriuretic peptide. Endocr J 1997, 44: 389-93.
51. Borghi, C., Esposti, D.D., Immordino, V. et al. Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. Am J Obstet Gynecol 2000, 183: 140-7.
52. Ikeda, T., Matsuda, K., Itoh, H. et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 1997, 133: 307-14.
53. Wallen, T., Landahl, S., Hedner, T., Saito, Y., Masuda, I., Nakao, K. Brain natriuretic peptide in an elderly population. J Intern Med 1997, 242: 307-11.
54. Rossi, A., Enriquez-Sarano, M., Burnett, J.C. Jr., Lerman, A., Abel, M. D., Seward, J.B. Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000, 35: 1256-62.
55. Berendes, E., Walter, M., Cullen, P. et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997, 349: 245-9.
56. Tomida, M., Muraki, M., Uemura, K., Yamasaki, K. Plasma concentration of brain natriuretic peptide in patients with subarachnoid hemorrhage. Stroke 1998, 29: 1584-7.
57. Sviri, G.E., Feinsod, M., Soustiel, J.F. Brain natriuretic peptide and cerebral vasospasm in subarachnoid hemorrhage. Clinical and TCD correlations. Stroke 2000, 31: 118-22.
58. Masters, R.C., Davies, R.A., Velnot, J.P., Hendry, P.J., Smith, S.J., de Bold, A.J. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999, 100: 287-91.
59. Hjortdal, V.E., Stenbog, E.V., Ravn, H.B. et al. Neurohormonal activation late after cavopulmonary connection. Heart 2000, 83: 439-43.
60. McGregor, A., Richards, M., Espiner, E., Yandle, T., Ikram, H. Brain natriuretic peptide administration to man: Actions and metabolism. J Clin Endocr Metab 1990, 70: 1103-7.
61. Holmes, S.J., Espiner, E.A., Richards, A.M., Yandle, T.G., Frampton, C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocr Metab 1993, 76: 91-6.
62. La Villa, G., Fronzaroli, C., Lazzeri, C. et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J Clin Endocr Metab 1994, 78: 1166-71.
63. Jensen, K.T., Carstens, J., Pedersen, E.B. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998, 274: F63-72.
64. Clarkson, P.B., Wheeldon, N.M. Macleod, C., Coutie, W., MacDonald, T.M. Brain natriuretic peptide: Effect on left ventricular filling patterns in healthy patients. Clin Sci (Colch) 1995, 88: 159-64.
65. Lazzeri, C., La Villa, G., Bisi, G. et al. Cardiovascular function during brain natriuretic peptide infusion in man. Cardiology 1995, 86: 396-401.
66. Okumura, K., Yasue, H., Fujii, H. et al. Effects of brain (B-type) natriuretic peptide on coronary artery diameter and coronary hemodynamic variables in humans: Comparison with effects on systemic hemodynamic variables. J Am Coll Cardiol 1995, 25: 342-8.
67. Cargill, R.I., Struthers, A.D., Lipworth, B. J. Comparative effects of atrial natriuretic peptide and brain natriuretic peptide on the aldosterone and presser responses to angiotensin II in man. Clin Sci (Colch) 1995, 88: 81-6.
68. Richards, A.M., Crozier, I.G., Holmes, S.J., Espiner, E.A., Yandle, T.G., Frampton, C. Brain natriuretic peptide: Natriuretic and endocrine effects in essential hypertension. J Hypertens 1993, 11: 163-70.
69. La Villa, G., Bisi, G., Lazzeri, G. Cardiovascular effects of brain natriuretic peptide in essential hypertension. Hypertension 1995, 25: 1053-7.
70. Pigeon, G.B., Richards, A.M., Nicholls, M.G., Espiner, E.A., Yandle, T.G., Frampton, C. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension 1996, 27: 906-13.
71. Lazzeri, C., Franchi, F., Porciani, C. et al. Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension. Am J Hypertens 1995, 8: 799-807.
72. Takeda, T., Kohno, M. Brain natriuretic peptide in hypertension. Hypertens Res 1995, 18: 259-66.
73. Yoshimura, M., Yasue, H., Morita, E. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991, 84: 1581-8.
74. Clarkson, P.B., Wheeldon, N.M., MacFadyen, R.J., Pringle, S.D., MacDonald, T.M. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation 1996, 93: 2037-42.
75. Hobbs, R.E., Miller, L.W., Bott-Silverman, C., James, K.B., Rincon, G., Grossbard, E.B. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 78: 896-901.
76. Yasue, H., Yoshimura, M. Natriuretic peptides in the treatment of heart failure. J Card Fail 1996, 2(4, Suppl.): S277-85.
77. Marcus, L.S., Hart, D., Packer, M. et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996, 94: 3184-9.
78. Lainchbury, J.G., Richards, A.M., Nicholls, M.G. et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension 1997, 30: 398-404.
79. Jensen, K.T., Eiskjaer, H., Carstens, J., Pedersen, E.B. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Colch) 1999, 96: 5-15.
80. Nakamura, M., Arakawa, N., Yoshida, H., Makita, S., Niimuma, H., Hiramori, K. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am Heart J 1998, 135: 414-20.
81. Mills, R.M., Le Jemtel, T.H., Horton, D.P. et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999, 34: 155-62.
82. Colucci, W.S., Elkayam, U., Norton, D.P. et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000, 343: 246-53.
83. Luchner, A., Burnett, J.C. Jr., Jougasaki, M., Hense, H.W., Riegger, G.A., Schunkert, H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study. J Am Coll Cardiol 1998, 32: 1839-44.
84. Tsutamoto, T., Wada, A., Maeda, K. et al. Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am Heart J 1997, 134: 910-6.
85. Florkowski, C.M., Richards, A.M., Espiner, E.A., Yandle, T.G., Sybertz, E., Frampton, C.M. Lowdose brain natriuretic peptide infusion in normal men and the influence of endopeptidase inhibition. Clin Sci (Colch) 1997, 92: 255-60.
86. Lainchbury, J.G., Richards, A.M., Nicholls, M.G., Espiner, E.A., Yandle, T.G. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. J Clin Endocr Metab 1999, 84: 723-9.
87. McDonell, G., Coutie, W., Shaw, C., Buchanan, K.D., Struthers, A.D., Nicholls, D.P. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol 1997, 43: 329-32.
88. Ferro, C.J., Spratt, J.C., Haynes, W.G., Webb, D.J. Inhibition of neutral endopeptidase caused vasoconstriction of human resistance vessels in vivo. Circulation 1998, 97: 2323-30.
89. Kentsch, M., Otter, W., Drummer, C., Notges, A., Gerzer, R., Muller-Esch, G. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol 1996, 51: 269-72.
90. McLean, D.R., Ikram, H., Garlick, A.H., Richards, A.M., Nicholls, M.G., Crozier, I.G. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000, 36: 479-86.